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Abstract 
Objective: To explore the prevalence of the perfusion-weighted imaging (PWI) - diffusion-
weighted imaging (DWI) mismatch and response to intravenous thrombolysis in the WAKE-UP 
trial.  
Methods: We performed a prespecified post-hoc analysis of ischemic stroke patients screened for 
DWI - fluid-attenuated inversion recovery (FLAIR) mismatch in WAKE-UP who underwent PWI. 
We defined PWI-DWI mismatch as ischemic core volume <70 ml, mismatch volume >10 ml and 
mismatch ratio >1.2. Primary efficacy endpoint was a modified Rankin Scale score of 0-1 at 90 
days, adjusted for age and symptom severity.  
Results: Of 1,362 magnetic resonance imaging (MRI) screened patients, 431 underwent PWI. Of 
these, 57 (13%) had a double mismatch, 151 (35%) only a DWI-FLAIR mismatch and 54 (13%) 
only a PWI-DWI mismatch. DWI-FLAIR mismatch was more prevalent than PWI-DWI mismatch 
(48%; 95% CI 43%-53% vs  26%; 95% CI 22%-30%, p<0.0001). Screening for either one of the 
mismatch profiles resulted in a yield of 61% (95% CI 56%-65%). Prevalence of PWI-DWI 
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mismatch was similar in patients with (27%) or without (24%) DWI-FLAIR mismatch (p= 0.52). 
In an exploratory analysis in the small subgroup of 208 randomized patients with PWI, PWI-DWI 
mismatch status did not modify the treatment response (p for interaction= 0.73).  
Interpretation: Evaluating both the DWI-FLAIR and PWI-DWI mismatch pattern in patients with 
unknown time of stroke onset will result in the highest yield of thrombolysis treatment. The 
treatment benefit of alteplase in patients with a DWI-FLAIR mismatch seems not merely driven 





Advanced neuroimaging techniques identify patients who benefit from intravenous reperfusion 
therapy in the extended time window after stroke onset and when onset time is unknown. Magnetic 
resonance imaging (MRI) provides more insights into the parenchymal and perfusion status in 
comparison to computed tomography (CT), although MRI is less accessible in stroke centers 
worldwide.  
The presence of a diffusion-weighted imaging (DWI) – fluid-attenuated inversion recovery 
(FLAIR) mismatch is an imaging pattern revealed in patients who present in the 4.5 hour time 
window after stroke onset. Determining this mismatch in patients with unknown time of stroke 
onset is an interesting approach to increase the amount of thrombolysis eligible patients.1 The 
Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke (WAKE-UP) trial randomized 
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patients with a DWI-FLAIR mismatch to placebo or alteplase, and indeed showed a treatment 
response similar to that observed in previous clinical trials within the therapeutic time window in 
patients with known stroke onset times. 2 DWI and perfusion-weighted imaging (PWI) offer an 
alternative mismatch paradigm that distinguishes ischemic from potentially salvageable tissue. 3 
Since almost 20% of stroke patients present with unknown time of stroke onset 4, 5, imaging 
identification of potential responders to reperfusion treatment is of great importance. It is unknown 
whether the two different mismatch patterns identify different patient groups or signify different 
magnitude of treatment response to intravenous thrombolysis. To explore this question, we 
conducted a prespecified post-hoc analysis of the WAKE-UP trial. We analyzed the individual and 
combined yield of each mismatch paradigm and investigated whether an association between both 
mismatch profiles exists. We also studied the interaction between the presence of a PWI-DWI 
mismatch and treatment with alteplase in patients randomized in WAKE-UP.  
 
Methods 
Study design and patients 
In this post-hoc analysis, we analyzed clinical and neuroimaging data from the subset of ischemic 
stroke patients screened in the WAKE-UP trial with PWI at baseline. The WAKE-UP trial was an 
investigator-initiated, multicenter, randomized, double blind, placebo-controlled clinical trial. A 
detailed description can be found in the original publication. 2 Main inclusion criteria were age 
between 18 and 80 years of age, independency before the stroke, unknown onset of stroke 
symptoms and time from last seen well >4.5 hours. Treatment had to be initiated within 4.5 hours 
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of symptom recognition. Patients eligible for thrombectomy, with severe stroke defined as National 
Institute of Health Stroke Scale (NIHSS) >25, with contraindications to alteplase (except for the 
time criterion) and with insufficient imaging quality were excluded. Patients fulfilling these criteria 
were screened with MRI between September 2012 and June 2017 (screened patients) (Fig 1, panel 
A). If a DWI lesion was present in the absence of a FLAIR hyperintense signal in the corresponding 
region, patients were randomized to alteplase or placebo (randomized patients). Patients without 
DWI-FLAIR mismatch were not randomized. The other main imaging exclusion criteria were the 
absence of a DWI lesion, DWI lesions larger than one third of the middle cerebral artery territory, 
diagnosis of hemorrhagic stroke or severe motion artefacts. Centers could decide whether they used 
MRI as first imaging modality or CT followed by MRI. National or local ethics committees or 
institutional review boards approved the trial. Informed consent was signed by patients or their 
legal representatives, according to national and local regulations.   
 
Image analysis 
In the original trial, imaging was performed at baseline and 22-36 hours after randomization. The 
standard MRI protocol consisted of DWI, FLAIR, time-of-flight magnetic resonance angiography 
(TOF-MRA) and gradient echo (GE) or susceptibility-weighted imaging (SWI). In a subset of 
patients, PWI (echoplanar T2* weighted sequence with gadolinium contrast bolus) was added to 
the protocol. Performing PWI was left to the discretion of the local investigator. In the WAKE-UP 
trial, local investigators visually rated the DWI-FLAIR mismatch. PWI was not used to guide 
randomization in the WAKE-UP trial. In the current analysis, we focused on patients with available 
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PWI at baseline. Automated analysis and calculation of DWI and PWI lesion volumes was 
performed using the RAPID software (iSchemaView, Menlo Park, CA, version 4.9 and 5.0), which 
identifies ischemic core based on a threshold <620*10-6mm2/s on the apparent diffusion coefficient 
(ADC) and the PWI lesion volume by the time to maximum of the residue function (Tmax) with a 
threshold of > 6s (Fig 2). We defined PWI-DWI mismatch according to the imaging criteria used 
in the EXTEND trial 3: core (DWI) lesion volume < 70 ml, absolute mismatch volume > 10 ml 
(PWI lesion - DWI lesion) and mismatch ratio >1.2 (PWI lesion/DWI lesion). After automated 
RAPID analysis, we manually adjusted the outputs if the selection of the arterial input function 
(AIF) or venous output function (VOF) was suboptimal based on visual inspection of the AIF and 
VOF curve generated by RAPID. Artifacts on the core or hypoperfusion map were manually 
removed after visual inspection of all generated maps. On baseline imaging, we manually 
delineated the DWI lesion volume with Horos software 6 if a lesion was not correctly identified by 
RAPID. Adjustment of AIF or VOF, removal of artifacts and manual delineation was done by L.S., 
blinded to clinical information. Double mismatch refers to the presence of both a DWI-FLAIR and 
PWI-DWI mismatch. 
 
Outcome measures  
The primary efficacy end point was defined as a modified Rankin Scale (mRS) score of 0 or 1 at 
90 days. This scale ranges from 0 (no symptoms) to 6 (dead), with values of 0 or 1 representing 
patients with a favorable functional outcome.7 Secondary efficacy end points were the ordinal score 
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on the mRS at 90 days. Safety end points were death or dependency (mRS 4-6) at 90 days and 
death at 90 days.  
 
Statistical analysis 
We used a McNemar test to compare the diagnostic yield of the DWI-FLAIR and PWI-DWI 
mismatch in screened patients. The proportions of PWI-DWI mismatch patients with or without a 
DWI-FLAIR mismatch were compared using a chi-square test. We compared baseline 
characteristics between randomized patients with and without PWI at baseline, between patients 
with a double mismatch versus only a DWI-FLAIR mismatch and between treatment arms in 
patients with a double mismatch and with only a DWI-FLAIR mismatch. Statistical analysis of 
treatment effect was performed in the intention-to-treat population for all patients with available 
information on clinical endpoints. We studied the interaction between the presence of the PWI-
DWI mismatch and treatment with alteplase on the primary end point using an unconditional 
logistic regression analysis, adjusted for age and NIHSS score (similar as in the original paper 2), 
fitted to estimate the odds ratio and its 95% confidence interval. We performed subgroup analyses 
on the stratification variable PWI-DWI mismatch. We analyzed the categorical shift in the 
distribution of the modified Rankin scale towards a better outcome by fitting a proportional-odds 
logistic regression model, resulting in a common odds ratio. Safety endpoints were analyzed with 
an unconditional logistic regression model, adjusted for age and NIHSS score, fitted to estimate 
the odds ratio and its 95% confidence interval. Statistical analyses were conducted in SAS software 
version 9.4 (SAS Institute) and R.8 A p-value of <0.05 was considered significant.  






Of 1,362 screened patients, 227/503 (45%) randomized patients and 245/859 (29%) non-
randomized patients underwent PWI. In total, 41 patients were excluded from the analysis because 
of insufficient PWI or DWI quality, resulting in successful mismatch analysis in 208 of the 
randomized and in 223 of the non-randomized patients (Fig 1 panel A). We manually adjusted 
arterial input or venous output function in 12 subjects and removed artifacts in 87 subjects. 
 
Diagnostic yield  
Of all 431 screened patients with PWI at baseline, a DWI-FLAIR mismatch was identified in 208 
(48%; 95% confidence interval [CI], 43%-53%) patients. Of these, 57 presented with a double 
mismatch and 151 with only a DWI-FLAIR mismatch. A total of 54 patients (13%) presented with 
only a PWI-DWI mismatch and were consequently not randomized in WAKE-UP. Fewer patients 
had a PWI-DWI mismatch (n=111; 26%; 95% CI, 22%-30%) than a DWI-FLAIR mismatch 
(p<0.0001). MRI-based selection of patients by any of the mismatch paradigms would have 
identified 262 patients as potentially eligible (61%; 95% CI,56%-65%) (Fig 1 panel A, B and C).  
 
Relationship between DWI-FLAIR and PWI-DWI mismatch 
We did not identify an association between the DWI-FLAIR and PWI-DWI mismatch since the 
frequency of a PWI-DWI mismatch was similar in randomized patients with DWI-FLAIR 
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mismatch and non-randomized patients without DWI-FLAIR mismatch (57/208, 27% vs 54/223, 
24%, p=0.52).  
 
Characteristics of randomized patients  
Baseline characteristics of randomized patients with versus without available PWI and baseline 
characteristics of randomized patients with a double mismatch versus only a DWI-FLAIR 
mismatch can be found in the supplementary data. The median NIHSS score was higher in patients 
with a double mismatch compared to those with only a DWI-FLAIR mismatch (8; IQR, 5-13 vs 5; 
IQR, 3-8, p<0.0001). RAPID analysis identified larger DWI (8 ml; IQR, 0-18 vs 0 ml; IQR, 0-8, 
p=0.007) and PWI lesion volumes (50 ml; IQR, 26-89 vs 0 ml; IQR,0-7, p<0.0001) in patients with 
a double mismatch. Any (80% vs 19%, p<0.0001) and large (59% vs 9%, p<0.0001) vessel 
occlusions were more frequent in patients with a double mismatch. Baseline characteristics per 
treatment arm of randomized patients with only a DWI-FLAIR mismatch and with a double 
mismatch are described in table 1 and 2. Of 57 patients with a double mismatch, 32 patients were 
assigned to alteplase and 25 to placebo. Patients in the alteplase group were older compared to 
patients in the placebo group (mean age 68.25; Standard deviation (SD) 11.31 versus 64.68; SD 
8.91, p=0.045). There were no significant differences in baseline characteristics in patients with 
only a DWI-FLAIR mismatch treated with alteplase versus placebo. Of 208 randomized patients, 
8 were lost to follow up (6 treated with alteplase and 2 treated with placebo).  
 
Efficacy and safety outcomes  
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Information on the primary efficacy end point was available for 200 randomized patients (145/151 
with only a DWI-FLAIR mismatch, 55/57 with a double mismatch). In an exploratory analysis, the 
presence of a PWI-DWI mismatch in addition to a DWI-FLAIR mismatch did not modify the 
treatment response in the small subgroup of 200 patients of the WAKE-UP trial (p for interaction= 
0.73). In patients with only a DWI-FLAIR mismatch, 45/76 (59%) receiving alteplase and 35/69 
(51%) receiving placebo achieved a favorable outcome at 90 days (odds ratio 1.44; 95% CI 0.71-
2.91). In patients with a double mismatch, 14/30 (47%) treated with alteplase versus 9/25 (36%) 
receiving placebo reached a favorable outcome at 90 days (odds ratio 1.86; 95% CI 0.54-6.44) 
(table 3).  
In addition, we explored the clinical outcomes over the total range of the modified Rankin Scale. 
In randomized patients with a DWI-FLAIR mismatch, there was no interaction between the 
presence of a PWI-DWI mismatch and treatment with alteplase (p for interaction=0.69). The 
median mRS score at 90 days in patients with a double mismatch was 2 (IQR, 1-4) in the alteplase 
group and 3 (IQR, 1-3) in the placebo group (common odds ratio 1.83; 95% CI 0.68-4.93, p=0.23; 
Fig 2 panel A, table 3). In patients with only a DWI-FLAIR mismatch, the median mRS score at 
90 days was 1 (IQR, 1-2) in both treatment groups (common odds ratio 1.45; 95% CI 0.80-2.62, 
p=0.22; Fig 2 panel B.).   
 
Death at 90 days and death or dependency (mRS 4-6) at 90 days did not differ between patients 
treated with alteplase or placebo (table 3).  
 




In this prespecified post hoc analysis of the WAKE-UP trial, we evaluated the percentage of 
patients with unknown stroke onset still eligible for thrombolysis based on findings on MRI. We 
identified up to 61% of ischemic stroke patients fulfilling imaging criteria for acute intravenous 
treatment by the DWI-FLAIR and/or PWI-DWI mismatch pattern. In a relatively small sample 
size, the presence of a PWI-DWI in addition to a DWI-FLAIR mismatch did not modify the effect 
of treatment with alteplase.  
The yield of the DWI-FLAIR mismatch to select patients eligible for thrombolysis in the unknown 
time window was double that of the PWI-DWI mismatch pattern. However, a substantial 
proportion of patients (13%) presented with a PWI-DWI mismatch in the absence of a DWI-FLAIR 
mismatch. Few trials investigating the PWI-DWI or perfusion lesion-ischemic core mismatch have 
reported the frequency of mismatch patterns among screened patients who were otherwise eligible 
for thrombolysis. Previously, studies investigating the PWI-DWI mismatch in patients with known 
stroke onset times in the 0-6 hour time window after stroke onset reported rates of 54% 9 and 88%.10 
The PRE-FLAIR study revealed a DWI-FLAIR mismatch in 38% of patients with known stroke 
onset times between 0-12 hours. 1 A post-hoc analysis of data from the AXIS2 trial found a similar 
yield of 44% for the DWI-FLAIR mismatch, but a higher yield of 72% for the PWI-DWI mismatch, 
resulting in a yield of 80% when screening for both mismatch profiles.11 The high proportion of 
the PWI-DWI mismatch probably resulted from the inclusion of patients with a DWI lesion of at 
least 15 ml, excluding small lesion strokes that are less likely to reveal a penumbral pattern. In 
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contrast, the WAKE-UP trial revealed very small core lesion volumes in a large proportion of 
screened patients.2  
We found no difference in the proportions of a PWI-DWI mismatch in patients with or without 
DWI-FLAIR mismatch. The presence of an association would suggest a mutual underlying disease 
mechanism 11 in which collaterals could play a role. In patients with good collaterals the association 
between time and development of a FLAIR hyperintense signal within the DWI lesion was less 
pronounced compared to patients with poor collateral status. 12 Good collaterals can be assumed in 
patients with a PWI-DWI mismatch, resulting in an association between the two mismatch 
patterns.13 However, other studies could not confirm the association between the severity of 
hypoperfusion and development of a FLAIR hyperintense signal over time. 14,15 The lack of 
association between both mismatch profiles in our study population might be due to the fact that 
only one third of patients had a visible vessel occlusion and stroke severity was rather moderate.  
We explored the modifying role of the presence of a PWI-DWI mismatch on treatment related 
outcome in patients with a DWI-FLAIR mismatch. Unfortunately the sample size for this 
subanalysis was rather small which is a limitation of this study. However, we found no interaction 
between the presence of a PWI-DWI mismatch and treatment. Since we lack power in our 
population, the presence of a synergistic effect of both mismatches on treatment response compared 
to the presence of either one of the mismatch profiles needs further study. In addition, half of the 
patients encountered with a PWI-DWI mismatch were not randomized based on the absence of a 
DWI-FLAIR mismatch and therefore their response to treatment could not be assessed. 
This article is protected by copyright. All rights reserved.
 
 
Since around 20% of patients present with unknown stroke onset time 4, 5, implementing MRI-
guided patient selection has a great relevance for treating ischemic stroke. In contrast to the PWI-
DWI mismatch, which can also be appreciated on CT perfusion as perfusion lesion-ischemic core 
mismatch, the DWI-FLAIR mismatch can only be evaluated using MRI. An approach using MRI 
may be more inclusive than one based on CT perfusion, given the high yield of the DWI-FLAIR 
mismatch. Multimodal MRI with DWI, FLAIR, PWI, GE or SWI and TOF-MRA is a feasible and 
probably the most inclusive approach to identify thrombolysis eligible patients in the unknown 
time window. We cannot extrapolate our findings to thrombectomy eligible patients in the 
unknown or extended time window, in which there is only evidence for the perfusion lesion-
ischemic core or clinical-core mismatch, but not the DWI-FLAIR mismatch.16, 17  
In conclusion, given their high combined yield, screening for the presence of both mismatch 
profiles by MRI with PWI, DWI and FLAIR is likely the most inclusive approach to identify 
ischemic stroke patients still eligible for intravenous thrombolysis in the unknown time window.  
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Figure 1. (A) Schematic overview of patients screened and/or randomized in the original WAKE-
UP trial and those included in the current post-hoc analysis. (B) Prevalence of each mismatch type 
in screened and/or randomized patients with available PWI. Numbers in the bars indicate the 
percentage of all screened patients with PWI with a certain mismatch type. (C) 2 by 2 table with 
DWI-FLAIR and PWI-DWI mismatch as classifiers, showing the number of patients per group. 
Double mismatch refers to the presence of both the PWI-DWI and DWI-FLAIR mismatch. PWI: 
perfusion-weighted imaging; DWI: diffusion-weighted imaging; FLAIR: fluid attenuated inversion 
recovery.  




Figure 2. Imaging examples (left) and distributions of scores on the modified Rankin Scale at 90 
days (right) in patients with a double mismatch and DWI-FLAIR mismatch only. (A) Double 
mismatch refers to the presence of both the PWI-DWI and DWI-FLAIR mismatch. Automated 
RAPID analysis shows a PWI-DWI mismatch (core < 70 ml, mismatch ratio > 1.2, mismatch 
volume > 10 ml). The core lesion is delineated on DWI (magenta) and the time to maximum (Tmax) 
> 6s volume on PWI (green). The distribution of scores on the modified Rankin Scale (mRS) at 90 
days shows no significant difference in patients treated with alteplase versus placebo in the 
subgroup of patients with a double mismatch (common odds ratio 1.83; 95% CI, 0.68-4.93; 
p=0.23). Numbers in the bars indicate the percentage of patients for each score on the mRS. (B) In 
patients with only a DWI-FLAIR mismatch, automated RAPID analysis reveals no PWI-DWI 
mismatch. The core lesion is delineated on DWI (magenta) and the time to maximum (Tmax) > 6s 
volume on PWI (green). The distribution of scores on the modified Rankin Scale (mRS) at 90 days 
shows no significant difference in patients treated with alteplase versus placebo in the subgroup of 
patients with only a DWI-FLAIR mismatch (common odds ratio 1.45; 95% CI 0.80-2.62; p=0.22). 
Numbers in the bars indicate the absolute number of patients for each score on the mRS. PWI: 

























Table 1. Baseline demographic characteristics of randomized patients with a double 
mismatch and only DWI-FLAIR mismatch allocated to alteplase versus placebo 
 Only DWI-FLAIR mismatch Double mismatch 
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N = 151 N = 57 
  
Alteplase 
N = 80 
Placebo 





N = 25 
p-value 
Age, mean (SD), years 63.74 (11.92) 63.73 (13.90) 0.60 68.25 (11.31) 64.68 (8.91) 0.05 
Male Gender, No. (%) 56 (70) 49 (69) 1.0 17 (53) 15 (60) 0.79 
Medical history or risk factors  
          Arterial hypertension 
No. (%)a 
40 (50) 34 (48) 0.74 16 (50) 14 (56) 0.79 
          Diabetes mellitus No. 
(%)b 
9 (11) 15 (21) 0.12 6 (19) 5 (20) 0.66 
          Hypercholesterolemia 
No. (%)c 
33 (41) 22 (31) 0.38 9 (28) 13 (52)  0.17 
          Atrial fibrillation No. 
(%)d 
6 (8) 6 (8) 1.0 6 (19) 6 (24) 0.75 
          History of ischemic 
stroke No. (%)e 
13 (16) 7 (10) 0.34 4 (13) 2 (8) 0.69 
aData on arterial hypertension were missing for 1 patient treated with placebo with only DWI-FLAIR mismatch. 
bData on diabetes mellitus were missing for 1 patient treated with alteplase with only DWI-FLAIR mismatch and 2 patients treated 
with alteplase.with double mismatch. 
cData on hypercholesterolemia were missing for 2 patients treated with alteplase and 1 with placebo with only DWI-FLAIR 
mismatch and in 5 patients treated with alteplase and 1 with placebo with double mismatch.  
dData on atrial fibrillation were missing for 2 patients treated with alteplase and 1 with placebo with only DWI-FLAIR mismatch. 
eData on history of ischemic stroke were missing for 1 patient treated with alteplase with only DWI-FLAIR mismatch. 
SD: standard deviation; No: Number; IQR: interquartile range 
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Table 2: Baseline stroke, imaging and treatment characteristics of randomized patients with 
a double mismatch and only DWI-FLAIR mismatch allocated to alteplase versus placebo 
 
Only DWI-FLAIR mismatch 
N = 151 
Double mismatch 
N = 57 
  
Alteplase 
N = 80 
Placebo 






N = 25 
p-
value 
Reason for unknown time of symptom onset   0.94  0.48 
          Night sleep, No. (%) 74 (93) 64 (90)  28 (88) 24 (96)  
          Day sleep, Aphasia or other, No. (%) 6 (8) 7 (10)  4 (13) 1 (4)  
Time between LSW point and symptom 











NIHSS sum score, median (IQR) 5 (3-8) 5 (3-8) 0.48 7.5 (5-13) 9 (5-12) 0.64 
DWI lesion volume at baseline, median 
(IQR), ml 
0 (0-10) 0 (0-7) 0.45 8 (0-17) 3 (0-28) 0.83 
PWI lesion volume at baseline, median 
(IQR), ml 
0 (0-8) 0 (0-5) 0.24 50 (28-75) 50 (21-109) 0.74 
Time from symptom recognition to MRI 











Time from symptom recognition to 











Time between LSW and treatment initiation 











Vessel occlusion on time-of-flight MRAd  
Any, No. (%) 17 (22) 11 (16) 0.40 26 (84) 19 (76) 0.51 
Large vessel occlusion, No. (%) 9 (12) 4 (6) 0.25 18 (58) 15 (60) 1.0 
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aTime between last seen well point and symptom recognition was missing for 4 patients treated with alteplase and 3 patients 
treated with placebo with only DWI-FLAIR mismatch and 3 patients treated with alteplase.and 1 patient treated with placebo with 
double mismatch. 
bTime from symptom recognition to treatment was missing for 2 patients treated with alteplase and 1 patient treated with placebo 
with only DWI-FLAIR mismatch and 1 patient treated with alteplase.with double mismatch. 
cTime between last seen well point and treatment initiation was missing for 5 patients treated with alteplase and 4 patients treated 
with placebo with only DWI-FLAIR mismatch and 4 patients treated with alteplase and 1 patient treated with placebo with double 
mismatch 
dAny vessel occlusion and large vessel occlusion was missing for 2 patients treated with alteplase and 1 with placebo with only 
DWI-FLAIR mismatch and for 1 patient treated with alteplase with double mismatch. Large vessel occlusion was defined as an 
occlusion of the intracranial internal carotid artery or main stem of the middle cerebral artery. 
No: Number; LSW: last seen well;  IQR: interquartile range; NIHSS: national Institutes of Health Stroke Scale; DWI: diffusion-




























Table 3: Efficacy and Safety outcomes in patients with a double mismatch treated with 














mRS score 0 or 1, No. (%)b 14 (47) 9 (36) OR 1.86 (0.54-6.44) 0.33 
Median mRS score (IQR)c  2 (1-4) 3(1-3) cOR 1.83 (0.68-4.93) 0.23 
Safety Outcome  
Death at 90 days, No. (%)f 3 (9) 0 (0) OR 
 <1.0 10-3 (<1.0 
10-3 -  > 9.9 102) 
0.95 
Death or dependency at 90 days, No. 
(%)g 
8 (27) 5 (20) OR 0.87 (0.20-3.85) 0.86 
aOdds Ratio’s (OR) and common Odds Ratio’s (cOR) were adjusted for the stratification variables age and symptom severity. 
bModified Rankin Scale (mRS) scores of 0 or 1 were considered the favorable outcomes. The primary efficacy outcome was 
analyzed in 30 patients in the alteplase group and 25 patients in the placebo group. Two patients in the alteplase group were lost to 
follow up. 
cCategorical shift in the distribution of mRS scores between the two treatment groups was analyzed in 30 patients in the alteplase 
group and 25 patients in the placebo group. Two patients in the alteplase group were lost to follow up. 
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fPrimary safety outcome death at 90 days was analyzed in 32 patients in the alteplase group and 25 patients in the placebo group.  
gPrimary safety outcome death or mRS score 4-6 at 90 days was analyzed in 30 patients in the alteplase group and 25 patients in 
the placebo group. Two patients in the alteplase group were lost to follow up. 
IQR: interquartile range.  
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